Señales en vivo de LGND | Maximiza tus Ganancias con Getagraph.com

VENDER 115828 min ago

@ $73.34

Emitido: 14 feb 2024 @ 10:26

Retorno: 0.76%

Señal anterior: feb 13 - 09:30

Señal anterior: Comprar

Retorno: -1.89 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide...

Stats
Volumen de hoy	138 103
Volumen promedio	179 366
Capitalización de mercado	1.33B
EPS	$0 ( 2024-05-02 )
Próxima fecha de ganancias	( $1.130 ) 2024-05-07
Last Dividend	$0.456 ( 2010-07-02 )
Next Dividend	$0 ( N/A )
P/E	24.39
ATR14	$0.102 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Aryeh Jason	Buy	2 406	Common Stock
2024-04-30	Aryeh Jason	Sell	2 406	Non-Qualified Stock Option (right to buy)
2024-04-24	Kozarich John W	Buy	2 893	Common Stock
2024-04-24	Kozarich John W	Sell	2 893	Non-Qualified Stock Option (right to buy)
2024-03-25	Davis Todd C	Buy	3 556	Common Stock

INSIDER POWER
77.05
Last 99 transactions
Buy: 843 765 \| Sell: 95 185

Volumen Correlación

Largo: 0.33 (neutral)

Corto: 0.79 (moderate)

Signal:(61.287) Neutral

Ligand Pharmaceuticals Correlación

10 Correlaciones Más Positivas
ALSK	0.829
NVEC	0.811

10 Correlaciones Más Negativas
EMBCV	-0.842

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ligand Pharmaceuticals Correlación - Moneda/Commodity

-0.60
( weak negative )

-0.63
( weak negative )

-0.83
( strong negative )

-0.67
( moderate negative )

0.25
( neutral )

0.65
( weak )

Ligand Pharmaceuticals Finanzas

Annual	2023
Ingresos:	$131.31M
Beneficio Bruto:	$119.75M (91.20 %)
EPS:	$3.02

FY	2023
Ingresos:	$131.31M
Beneficio Bruto:	$119.75M (91.20 %)
EPS:	$3.02

FY	2022
Ingresos:	$196.25M
Beneficio Bruto:	$143.42M (73.08 %)
EPS:	$-0.310

FY	2021
Ingresos:	$277.13M
Beneficio Bruto:	$214.96M (77.56 %)
EPS:	$2.22

Financial Reports:

No articles found.

Ligand Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Ligand Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.02 - good (80.23%) | Divividend Growth Potential Score: 1.503 - No dividend growth expected in the near future

Information

First Dividend	$9.36	2007-04-03
Last Dividend	$0.456	2010-07-02
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$9.81	--
Avg. Dividend % Per Year	0.00%	--
Score	1.65	--
Div. Sustainability Score	8.02
Div.Growth Potential Score	1.503
Div. Directional Score	4.76	--

Next Divdend (Est)
(2026-09-30)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.65

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2007	$9.36	14.30%
2008	$0	0.00%
2009	$0	0.00%
2010	$0.456	3.50%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.378	1.500	2.44	3.66	[0 - 0.5]
returnOnAssetsTTM	0.0596	1.200	8.01	9.62	[0 - 0.3]
returnOnEquityTTM	0.0742	1.500	-0.287	-0.431	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	14.15	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	12.49	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.368	1.500	3.51	5.27	[0.2 - 2]
debtRatioTTM	0.00740	-1.500	9.88	-10.00	[0 - 0.6]
interestCoverageTTM	2.60	1.000	-0.148	-0.148	[3 - 30]
operatingCashFlowPerShareTTM	2.84	2.00	9.05	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.245	2.00	-0.122	-0.245	[0 - 20]
debtEquityRatioTTM	0.00880	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.920	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.0666	1.000	-0.669	-0.669	[0.1 - 0.6]
cashFlowToDebtRatioTTM	8.04	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.158	0.800	-2.28	-1.826	[0.5 - 2]
Total Score				8.02

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	26.00	1.000	7.47	0	[1 - 100]
returnOnEquityTTM	0.0742	2.50	-0.185	-0.431	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.245	2.00	-0.0815	-0.245	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.84	2.00	9.05	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0124	1.500	-3.25	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.378	1.000	3.06	0	[0.1 - 0.5]
Total Score				1.503

Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

Actualizaciones en tiempo real para Ligand Pharmaceuticals [LGND]

Upcoming Earnings Alert

Ligand Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for NASDAQ

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)